Department of Radiology

Publications

2021

Andrews EF, Jacqmot O, Gomes FN, Sha MF, Niogi SN, Johnson PJ. Characterizing the canine and feline optic pathways in vivo with diffusion MRI. Vet Ophthalmol. 2021.

Zhou L, Zhang Q, Spincemaille P, Nguyen TD, Morgan J, Dai W, et al. Quantitative transport mapping (QTM) of the kidney with an approximate microvascular network. Magn Reson Med. 2021;85(4):2247-2262.

Akerele MI, Karakatsanis NA, Forsythe RO, Dweck MR, Syed M, Aykroyd RG, et al. Iterative reconstruction incorporating background correction improves quantification of [F]-NaF PET/CT images of patients with abdominal aortic aneurysm. J Nucl Cardiol. 2021;28(5):1875-1886.

Dyakin VV, Dyakina-Fagnano NV, McIntire LB, Uversky VN. Fundamental Clock of Biological Aging: Convergence of Molecular, Neurodegenerative, Cognitive and Psychiatric Pathways: Non-Equilibrium Thermodynamics Meet Psychology. Int J Mol Sci. 2021;23(1).

Swerdlow RH, de Leon MJ, Marcus DL. Betahydroxybutyrate Consumption in Autopsy Brain Tissue from Alzheimer's Disease Subjects. J Alzheimers Dis Rep. 2021;5(1):135-141.

Robson PM, Vergani V, Benkert T, Trivieri MG, Karakatsanis NA, Abgral R, et al. Assessing the qualitative and quantitative impacts of simple two-class vs multiple tissue-class MR-based attenuation correction for cardiac PET/MR. J Nucl Cardiol. 2021;28(5):2194-2204.

Gabr MT, Deganutti G, Reynolds CA. Peptidomimetic-based approach toward inhibitors of microbial trimethylamine lyases. Chem Biol Drug Des. 2021;97(2):231-236.

Shah SA, Gautam R, Lowder R, Mauer EA, Carullo RB, Parlatore DE, et al. Quantitative Electroencephalographic Markers of Delirium in the Pediatric Intensive Care Unit: Insights From a Heterogenous Convenience Sample. J Neuropsychiatry Clin Neurosci. 2021;33(3):219-224.

Rehman AU, Zhen G, Zhong B, Ni D, Li J, Nasir A, et al. Mechanism of zinc ejection by disulfiram in nonstructural protein 5A. Phys Chem Chem Phys. 2021;23(21):12204-12215.

Butler T, Goldberg JD, Galvin JE, Maloney T, Ravdin L, Glodzik L, et al. Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemp Clin Trials. 2021;107:106488.